Vyome Holdings, Inc. (HIND)
| Market Cap | 15.48M -73.8% |
| Revenue (ttm) | 129,725 -67.1% |
| Net Income | -11.31M |
| EPS | -1.61 |
| Shares Out | 7.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,776 |
| Open | 2.265 |
| Previous Close | 2.210 |
| Day's Range | 2.205 - 2.265 |
| 52-Week Range | 1.750 - 10.966 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 11.50 (+421.54%) |
| Earnings Date | Aug 12, 2026 |
About HIND
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5′-monophosphate dehydrogenase enzyme... [Read more]
Financial Performance
In 2025, Vyome Holdings's revenue was $319,714, an increase of 24.43% compared to the previous year's $256,944. Losses were -$10.26 million, 609.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for HIND stock is "Buy." The 12-month stock price target is $11.5, which is an increase of 421.54% from the latest price.
News
Vyome names Jerry Leonard as CFO
In a regulatory filing, the company stated, “On August 27, 2026, the board of directors of Vyome (HIND) Holdings appointed Jerry Leonard as the company’s Chief Financial Officer. In connection…
Vyome reports Q2 EPS (10c)
Cash and cash equivalents were approximately $7.9 million as of June 30, 2026, compared with approximately $5.0 million as of December 31, 2025. Krishna Gupta, Chairman, Vyome (HIND) Holdings, said,…
Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND, “Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today ...
Vyome Holdings Quarterly report: Q2 2026
Vyome Holdings has published its Q2 2026 quarterly earnings report on August 12, 2026.
Vyome Holdings Earnings release: Q2 2026
Vyome Holdings released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Vyome announces CNIPA granted patent covering formula related to besifloxacin
Vyome (HIND) announces that the China National Intellectual Property Administration, CNIPA, has granted a patent covering formulation and therapeutic use claims relating to its proprietary besifloxaci...
Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #VT1953--Vyome Holdings, Inc. (NASDAQ: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated the...
Vyome Holdings Earnings Call Transcript: Q1 2026
Disciplined execution led to progress in immunoinflammatory and rare disease programs, with VT-1953 advancing toward pivotal trials and a strengthened capital structure. Cash position improved, and a strategic JAK inhibitor in-licensing expands future opportunities.
Vyome Holdings Quarterly report: Q1 2026
Vyome Holdings has published its Q1 2026 quarterly earnings report on June 3, 2026.
Vyome Holdings Earnings release: Q1 2026
Vyome Holdings released its Q1 2026 earnings on June 3, 2026, summarizing the period's financial results.
Vyome reports Q1 EPS (15c) vs. ($761.59) last year
Krishna Gupta, Chairman of Vyome (HIND), said, “Over the last several quarters, Vyome has executed with focus and discipline, advancing differentiated programs in areas of significant unmet medical ne...
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (Nasdaq: HIND)(“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports fi...
Vyome signs exclusive license agreement with Impetis
Vyome (HIND) Holdings announced the signing of an agreement with Impetis Biosciences, a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and…
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited (“Impetis”), a TATA Enterprise, that gives...
Vyome initiated with a Buy at Litchfield Hills
Litchfield Hills analyst Theodore O’Neill initiated coverage of Vyome (HIND) with a Buy rating and $8 price target The company’s drug development operating system repurposes an FDA-approved molecule f...
Vyome Holdings presents Phase 2 study results on VT-1953
Vyome Holdings (HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of Malign...
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026.
Vyome Holdings to present Phase 2 data on VT-1953 at AACR 2026
Vyome Holdings (HIND) will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and…
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical dat...
Vyome Holdings Proxy statement: Proxy filing
Vyome Holdings filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Vyome Holdings reports FY25 revenue $319.7k vs $246.9k last year
“Vyome is targeting one of the biggest challenges in the world today – inflammation. So many of our medical and mental problems are linked to increased inflammation. We are building…
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase.
Vyome Holdings Proxy statement: Proxy filing
Vyome Holdings filed a proxy statement on March 20, 2026, providing details for shareholder voting and corporate governance matters.
Vyome Holdings Annual report: Q4 2025
Vyome Holdings has published its Q4 2025 annual report on March 18, 2026.
Vyome Holdings publishes preclinical VT-1908 data
Vyome Holdings (HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed Journal of Ophthalmic In...